:

How Does Age Affect Immune Checkpoint Therapy Biomarkers?

According to research, the majority of new cancer diagnoses occur in patients over the age of 65, making the study of age-related immune changes critical. These changes profoundly influence the biomarkers used to predict response to immune checkpoint therapy, affecting treatment strategies and outcomes.